Prostatype Genomics AB (publ) (PROGEN.ST)
SEK 10.3
(-8.04%)
SEK 10.3
(-8.04%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.13 Million | -27.69 Million | -16.07 Million | -14.71 Million | -9.63 Million | -5.7 Million |
| Net Income | -41.43 Million | -29.08 Million | -15.62 Million | -17.4 Million | -8.54 Million | -9.31 Million |
| Depreciation & Amortization | 1.87 Million | 1.9 Million | 88.48 Thousand | 149.05 Thousand | 154.14 Thousand | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 9.82 Million | -511.15 Thousand | -536.93 Thousand | 1.92 Million | -1.79 Million | 3.41 Million |
| Other non-cash items | -5.47 Million | 4.31 Million | 713.9 Thousand | -994.86 Thousand | 558.7 Thousand | 194.57 Thousand |
| Investing Cash Flow | -8.56 Million | - | -2.49 Million | -3.25 Million | -3.26 Million | -4.66 Million |
| Investments in PPE | -8.56 Million | - | -2.49 Million | -3.25 Million | -3.26 Million | -4.66 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -4000.00 | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -8.49 Million | - | -2.49 Million | -1.71 Million | -3.23 Million | - |
| Financing Cash Flow | 28.91 Million | 18.85 Million | 23.04 Million | 31.13 Million | 7.37 Million | 8.1 Million |
| Debt repayment | -10.8 Million | -18.85 Million | -200 Thousand | -30.93 Million | -209.37 Thousand | -12.5 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 18.11 Million | - | - | 204.16 Thousand | - | 613.41 Thousand |
| Other Financing Activities | 18.11 Million | 37.7 Million | 23.24 Million | 20.72 Million | 7.58 Million | 7.5 Million |
| Accounts receivables | 980 Thousand | -1.42 Million | 125.48 Thousand | -79.41 Thousand | 4179.00 | - |
| Accounts payables | 8.86 Million | 912.85 Thousand | -875.33 Thousand | 1.73 Million | -4179.00 | - |
| Inventory | -21 Thousand | -260.00 | 212.92 Thousand | 269.05 Thousand | -64.6 Thousand | -251.94 Thousand |
| Other working capital | 8.86 Million | 912.85 Thousand | -875.33 Thousand | 1.37 Million | -1.73 Million | 3.66 Million |
| Cash at beginning of period | 4.81 Million | 20.32 Million | 15.86 Million | 2.69 Million | 8.2 Million | 10.47 Million |
| Cash at end of period | 2.68 Million | 11.48 Million | 20.32 Million | 15.86 Million | 2.69 Million | 8.2 Million |
| Capital Expenditure | -8.56 Million | - | -2.49 Million | -3.25 Million | -3.26 Million | -4.66 Million |
| Effect of forex changes on cash | -13 Thousand | - | - | -1.00 | - | - |
| Net cash flow / Change in cash | -2.12 Million | -8.84 Million | 4.46 Million | 13.16 Million | -5.51 Million | -2.27 Million |
| Free Cash Flow | -37.7 Million | -27.69 Million | -18.57 Million | -17.96 Million | -12.89 Million | -10.37 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.83 Million | -9.83 Million | -11.77 Million | -41.43 Million | -11.77 Million | -10.08 Million |
| Depreciation & Amortization | - | - | -460.26 Thousand | 1.87 Million | -460.26 Thousand | 469.26 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -1.97 Million | -1.97 Million | 6.6 Million | 9.82 Million | 6.6 Million | -1.44 Million |
| Other non-cash items | 199.5 Thousand | 199.5 Thousand | 1.22 Million | -5.47 Million | 1.22 Million | 1.00 |
| Investing Cash Flow | -3.26 Million | -3.26 Million | -4.31 Million | -8.56 Million | -4.31 Million | 5105.00 |
| Investments in PPE | - | - | -37.5 Thousand | -8.56 Million | -37.5 Thousand | -5090.00 |
| Acquisitions | - | - | - | - | - | 64.8 Thousand |
| Investment purchases | - | - | - | -4000.00 | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -3.26 Million | -3.26 Million | -4.27 Million | -8.49 Million | -4.27 Million | -59.7 Thousand |
| Financing Cash Flow | 14.4 Million | 14.4 Million | 4.21 Million | 28.91 Million | 4.21 Million | 20.57 Million |
| Debt repayment | - | - | - | -10.8 Million | - | -100 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 18.11 Million | - | 20.67 Million |
| Other Financing Activities | 14.4 Million | 14.4 Million | 4.21 Million | 18.11 Million | 4.21 Million | -100 Thousand |
| Accounts receivables | 169.5 Thousand | 169.5 Thousand | 2.73 Million | 980 Thousand | 2.73 Million | -2.12 Million |
| Accounts payables | - | - | - | 8.86 Million | - | 542.69 Thousand |
| Inventory | 1500.00 | 1500.00 | 45.1 Thousand | -21 Thousand | 45.1 Thousand | 3080.00 |
| Other working capital | -2.14 Million | -2.14 Million | 3.81 Million | 8.86 Million | 3.81 Million | 129.6 Thousand |
| Cash at beginning of period | - | - | - | 4.81 Million | 11.97 Million | 2.17 Million |
| Cash at end of period | -449 Thousand | -449 Thousand | -4.5 Million | 2.68 Million | 7.18 Million | 11.69 Million |
| Capital Expenditure | - | - | -37.5 Thousand | -8.56 Million | -37.5 Thousand | -5090.00 |
| Effect of forex changes on cash | 18.5 Thousand | 18.5 Thousand | -6500.00 | -13 Thousand | -6500.00 | -1.00 |
| Net cash flow / Change in cash | -449 Thousand | -449 Thousand | -4.5 Million | -2.12 Million | -4.78 Million | 9.52 Million |
| Free Cash Flow | -11.6 Million | -11.6 Million | -4.43 Million | -37.7 Million | -4.43 Million | -11.06 Million |
NDO
UCIX
SYBLY
ORIN
ARESF
MNIF